QUOTE AND NEWS
Benzinga  Nov 11  Comment 
Analysts at Piper Jaffray upgraded ICU Medical (NASDAQ: ICUI) from Neutral to Overweight. The price target for ICU Medical has been raised from $60.00 to $86.00. ICU Medical shares have gained 15.67% over the past 52 weeks, while the S&P 500...
TheStreet.com  Nov 10  Comment 
NEW YORK (TheStreet) -- Shares of Boulder Brands Inc. are up 2.85% to $9.01 in pre-market trading today, after the company was upgraded to "overweight" from "neutral" at Piper Jaffray. The firm said it raised Boulder Brands' rating because...
Benzinga  Nov 5  Comment 
Stratasys, Ltd. (NASDAQ: SSYS) reported its third quarter results on Wednesday morning which featured a better-than-expected earnings per share and revenue beat. Shares of Stratasys have plunged 12 percent, likely due to the company's lowered...
Benzinga  Nov 5  Comment 
Analysts at RBC Capital initiated coverage on Dominion Midstream Partners LP (NYSE: DM) with a Outperform rating. The target price for Dominion Midstream Partners is set to $38. Dominion Midstream's shares fell 2.57% to close at $30.30...
Benzinga  Nov 4  Comment 
Shares of Priceline Group Inc (NASDAQ: PCLN) tumbled on Tuesday following the company's weak third quarter results and troubling fourth quarter guidance. Michael Olson of Piper Jaffray defended shares on Tuesday, noting the more than 8 percent...
Benzinga  Nov 4  Comment 
Analysts at Piper Jaffray downgraded Leapfrog Enterprises (NYSE: LF) from Overweight to Neutral. The price target for Leapfrog Enterprises has been lowered from $8.50 to $5.50. Leapfrog shares have dropped 31.95% over the past 52 weeks, while...
Benzinga  Oct 30  Comment 
Analysts at Piper Jaffray upgraded The Finish Line (NASDAQ: FINL) from Neutral to Overweight. The price target for Finish Line has been raised from $28.00 to $31.00. Finish Line's shares closed at $25.74 in pre-market trading. Latest...
MarketWatch  Oct 27  Comment 
A Piper Jaffray equity analyst cut his price target on Sarepta Therapeutics Inc. Monday. The price-target cut came after the company said it will delay its new drug application for eteplirsen, a Duchenne Muscular Dystrophy treatment. Analyst...
Benzinga  Oct 16  Comment 
Analysts at Piper Jaffray upgraded Illumina (NASDAQ: ILMN) from Neutral to Overweight. The price target for Illumina has been raised from $166.00 to $192.00. Illumina shares have gained 87.08% over the past 52 weeks, while the S&P 500 index...





You may also be interested in articles related to Piper Jaffray Companies (PJC):
 




You have more usfuel info than the British had colonies pre-WWII.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki